PTC Therapeutics Inc (PTCT) - Total Liabilities
Based on the latest financial reports, PTC Therapeutics Inc (PTCT) has total liabilities worth $3.12 Billion USD as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore cash flow conversion of PTC Therapeutics Inc to assess how effectively this company generates cash.
PTC Therapeutics Inc - Total Liabilities Trend (2004–2025)
This chart illustrates how PTC Therapeutics Inc's total liabilities have evolved over time, based on quarterly financial data. Check PTC Therapeutics Inc (PTCT) liquid assets ratio to evaluate the company's liquid asset resilience ratio.
PTC Therapeutics Inc Competitors by Total Liabilities
The table below lists competitors of PTC Therapeutics Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Home BancShares Inc
NYSE:HOMB
|
USA | $18.59 Billion |
|
Keda Clean Energy Co Ltd
SHG:600499
|
China | CN¥14.23 Billion |
|
Shanghai RAAS Blood Products Co Ltd Class A
SHE:002252
|
China | CN¥5.44 Billion |
|
Sinopec Oilfield Service Corp
SHG:600871
|
China | CN¥68.67 Billion |
|
Credit Acceptance Corporation
NASDAQ:CACC
|
USA | $7.11 Billion |
|
Jfrog Ltd
NASDAQ:FROG
|
USA | $453.93 Million |
|
BRF SA ADR
NYSE:BRFS
|
USA | $46.19 Billion |
Liability Composition Analysis (2004–2025)
This chart breaks down PTC Therapeutics Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see PTCT market cap overview.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.35 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -15.18 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 1.07 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how PTC Therapeutics Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for PTC Therapeutics Inc (2004–2025)
The table below shows the annual total liabilities of PTC Therapeutics Inc from 2004 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $3.12 Billion | +11.18% |
| 2024-12-31 | $2.80 Billion | +3.27% |
| 2023-12-31 | $2.71 Billion | +32.23% |
| 2022-12-31 | $2.05 Billion | +5.99% |
| 2021-12-31 | $1.94 Billion | +12.18% |
| 2020-12-31 | $1.73 Billion | +67.69% |
| 2019-12-31 | $1.03 Billion | +33.96% |
| 2018-12-31 | $768.50 Million | +226.72% |
| 2017-12-31 | $235.22 Million | +57.06% |
| 2016-12-31 | $149.76 Million | +115.26% |
| 2015-12-31 | $69.57 Million | +100.20% |
| 2014-12-31 | $34.75 Million | +126.24% |
| 2013-12-31 | $15.36 Million | -52.40% |
| 2012-12-31 | $32.27 Million | -88.59% |
| 2011-12-31 | $282.75 Million | +4973.62% |
| 2005-12-31 | $5.57 Million | +27.97% |
| 2004-12-31 | $4.36 Million | -- |
About PTC Therapeutics Inc
PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to children and adults living with rare disorders in the United States and internationally. The company provides Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervo… Read more